Insulet Co. (NASDAQ:PODD) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 78.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,937 shares of the medical instruments supplier's stock after selling 50,279 shares during the quarter. Los Angeles Capital Management LLC's holdings in Insulet were worth $3,244,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Wedmont Private Capital raised its stake in Insulet by 3.5% during the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after purchasing an additional 48 shares during the period. Blue Trust Inc. raised its stake in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier's stock worth $1,264,000 after purchasing an additional 66 shares during the period. Greenleaf Trust raised its stake in Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier's stock worth $415,000 after purchasing an additional 72 shares during the period. Finally, UMB Bank n.a. raised its stake in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 81 shares during the period.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of research reports. Citigroup raised their target price on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research note on Tuesday, October 1st. BTIG Research raised their target price on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price on the stock. Piper Sandler raised their target price on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Finally, Barclays raised their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.27.

Insulet Stock Down 2.2 %

PODD stock traded down $6.04 during mid-day trading on Wednesday, hitting $269.06. 407,782 shares of the company were exchanged, compared to its average volume of 780,076. The company has a market capitalization of $18.87 billion, a PE ratio of 46.07, a price-to-earnings-growth ratio of 4.26 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $279.40. The firm has a fifty day simple moving average of $235.96 and a 200 day simple moving average of $206.47.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.